Chemokines and chemokine receptors: Potential therapeutic targets in systemic lupus erythematosus
- PMID: 39326198
- DOI: 10.1016/j.cyto.2024.156770
Chemokines and chemokine receptors: Potential therapeutic targets in systemic lupus erythematosus
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects connective tissue and can lead to multisystem organ damage. Chemokines are a class of small proteins that interact with receptors and participate in a variety of physiological functions, including cell growth, differentiation, apoptosis and distribution. They also play important roles in pathological processes, such as the inflammatory response, wound repair, tumor formation and metastasis. Previous studies have shown that the levels of chemokines and their receptors are elevated in the blood and inflamed tissues of SLE patients. In addition, chemokine ligand-receptor interactions control the recruitment of leukocytes into tissues, suggesting that chemokines and their receptors may be biomarkers and therapeutic targets for SLE. This review summarizes the causative role of chemokines and their receptors in SLE, as well as their clinical values and challenges as potential biomarkers and therapeutic targets.
Keywords: Biomarkers; Chemokine; Chemokine receptor; Systemic lupus erythematosus; Therapeutic target.
Copyright © 2024. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Chemokines and Chemokine Receptors in the Development of Lupus Nephritis.Mediators Inflamm. 2016;2016:6012715. doi: 10.1155/2016/6012715. Epub 2016 Jun 14. Mediators Inflamm. 2016. PMID: 27403037 Free PMC article. Review.
-
Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.Arthritis Res Ther. 2008;10(5):R112. doi: 10.1186/ar2510. Epub 2008 Sep 15. Arthritis Res Ther. 2008. PMID: 18793417 Free PMC article.
-
Chemokine blockade for lupus model mice.Front Biosci. 2008 Jan 1;13:2900-8. doi: 10.2741/2894. Front Biosci. 2008. PMID: 17981762 Review.
-
Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.Arthritis Res Ther. 2011 Jun 16;13(3):R88. doi: 10.1186/ar3363. Arthritis Res Ther. 2011. PMID: 21679442 Free PMC article.
-
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus.PLoS Med. 2006 Dec;3(12):e491. doi: 10.1371/journal.pmed.0030491. PLoS Med. 2006. PMID: 17177599 Free PMC article.
Cited by
-
CCL22 as a diagnostic and prognostic biomarker for pediatric-onset systemic lupus erythematosus.Clin Exp Med. 2025 Jul 8;25(1):235. doi: 10.1007/s10238-025-01790-0. Clin Exp Med. 2025. PMID: 40627196 Free PMC article.
-
Progress in structure-based drug development targeting chemokine receptors.Front Pharmacol. 2025 Jun 9;16:1603950. doi: 10.3389/fphar.2025.1603950. eCollection 2025. Front Pharmacol. 2025. PMID: 40552145 Free PMC article. Review.
-
Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review.Cureus. 2025 Feb 24;17(2):e79569. doi: 10.7759/cureus.79569. eCollection 2025 Feb. Cureus. 2025. PMID: 40151747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical